FURTHER DEVELOPMENT OF COLOVAC, A MULTI-ANTIGEN MULTI-PEPTIDE VACCINE, FOR COLON CANCER PREVENTION

进一步开发用于预防结肠癌的多抗原多肽疫苗 COLOVAC

• 批准号: 10021897
• 负责人: CLINTON GRUBBS
• 金额: $ 105.28万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2022-03-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10021897
• 关键词: Active Immunization; Acute; Adenomatous Polyposis Coli; Adult; Advisory Committees; Affinity; Age; Age-Years; Algorithms; Alleles; Antigen Targeting; Antigens; ApcMin/+ mice; Binding; CD8-Positive T-Lymphocytes; Cancer Center; Cancer Etiology; Cancer Patient; Cancer Vaccines; Cancerous; Cdc25B protein; Cessation of life; Chronic; Clinical Trials; Colorectal Cancer; DNA Vaccines; Development; Disease Outcome; Early Diagnosis; Epidermal Growth Factor Receptor; Epitopes; Family history of; Future; Gastrointestinal Hemorrhage; Genes; Genetic Diseases; Goals; Hereditary Nonpolyposis Colorectal Neoplasms; Human; Immune system; Immunity; Immunization; Immunologic Memory; Immunologics; Immunosuppression; Immunosuppressive Agents; Immunotherapy; Intercept; Intestines; Lesion; Malignant - descriptor; Malignant Neoplasms; Mediating; Naproxen; Non-Steroidal Anti-Inflammatory Agents; Normal tissue morphology; Oncogenic; PTGS2 gene; Peptide Vaccines; Peptides; Play; Polyps; Pre-Clinical Model; Premalignant; Premalignant Cell; Prevention strategy; Preventive; Preventive service; Preventive vaccine; Process; Proteins; Regimen; Reporting; Role; System; T cell response; Tissues; Toxic effect; Tumor Antigens; Tumor Burden; Tumor Immunity; Tumor-Derived; Vaccines; Woman; Work; anti-tumor immune response; antitumor effect; base; cancer diagnosis; cancer prevention; cancer risk; clinical application; colon cancer prevention; colorectal cancer prevention; colorectal cancer risk; colorectal cancer screening; design; healthy volunteer; high risk population; immune checkpoint blockade; immunogenic; immunogenicity; men; novel; overexpression; peptide based vaccine; screening; screening guidelines; side effect; synergism; tumor; tumorigenesis; tumorigenic

Colorectal cancer (CRC) is the third most common cancer diagnosed in men and women, and the second leading cause of cancer death in the US. The US Preventive Services Task Force recommends screening for colorectal cancer starting at age 50 years and continuing until 75 years of age for asymptomatic adults with average risk of CRC and without a family history of known genetic disorders associated with an increased risk of CRC such as Lynch syndrome or familial adenomatous polyposis (FAP). While the evidence supports that CRC-screening confers a substantial benefit overall, there will be an estimated 145,600 new CRC cases and 51,020 deaths from CRC expected in 2019. In addition to screening and early detection, prevention strategies that can further reduce the CRC risk will be of great benefit, in particular in high risk populations. A number of previous studies have shown that use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of cancers, including CRC. However, their extended use can be associated with serious side effects, such as gastrointestinal bleeding. Safer and more efficacious approaches are needed for durable long-term CRC prevention. Cancer vaccines targeting tumor-associated antigens (TAA) overexpressed in pre-cancerous and cancerous lesions may elicit antitumor immunity that intercepts tumorigenic process and eliminates precancerous cells before they progress to form a full-blown cancer. Recent advances in immunotherapies for various cancers have clearly shown that the immune system can mount effective antitumor immune responses if tumor-associated immunosuppression is abrogated, for example, by immune checkpoint blockade. It is conceivable that effective antitumor immunity may be more efficiently elicited by active immunization against TAA in the cancer prevention setting, as tumor-derived immunosuppressive mechanisms may play a lesser role in premalignant lesions. If long-term immunological memory can be established, such cancer vaccines can serve as a safer and more effective approach to cancer prevention. One of the most important steps toward developing effective cancer preventive vaccines is the selection of the antigens. Disis and colleagues have previously shown that high binding affinity across multiple HLA class II alleles predicts immunogenic human epitopes. They developed a scoring system designed to identify epitopes with optimal binding affinity and promiscuity across multiple class II alleles. Using the scoring algorithms, they demonstrated that peptides selected from the identified immunogenic hotspots of the target protein could induce robust antigen-specific type 1 T cell response in cancer patients and healthy volunteers. Immunization with these peptides mediated an antitumor effect in preclinical models of tumorigenesis. They further optimized the epitope selection process by eliminating Th2-epitopes from candidate peptides and demonstrated that highly robust protective immunity could be elicited by a multi-peptide vaccine with potent antitumor activity. Current approaches to the development of preventive vaccines for non-viral cancers are centered on strategies to target known oncogenic proteins. However, novel and more broadly applicable promising target antigens for preventive cancer vaccines may be identified from careful analyses of genes that are overexpressed in premalignant and malignant tissues but not in normal tissues. Disis et al. have recently reported highly immunogenic Th1-promoting epitopes from three TAAs, CDC25B, COX2 and EGFR, all of which are overexpressed in CRC and associated with poor disease outcomes. They showed these selected TAA-peptide based vaccine, referred to as Colovac, induced type 1 immunity and decreased tumor burden in preclinical models of intestinal tumorigenesis. Separately, her group has also demonstrated that NSAIDs significantly reduced polyp formation while increasing the number of CD8+ T-cell infiltrates in polyps in ApcMin/+ mice. This study is based on the work performed under the Task Order HHSN261201500036I/ HHSN26100004 (https://projectreporter.nih.gov/project_info_details.cfm?aid=9360921), which focused on determining immunologic synergy and antitumor activity of the combination regimen of Colovac and naproxen in preclinical models of intestinal tumorigenesis. The current study aims to further advance the Colovac vaccine towards clinical applications.

结直肠癌（CRC）是美国男性和女性中第三大最常见的癌症，也是导致癌症死亡的第二大原因。美国预防服务工作组建议，对于无症状、有平均结直肠癌风险且没有已知的与结直肠癌风险增加相关的遗传疾病家族史（如Lynch综合征或家族性腺瘤性息肉病（FAP））的成年人，从50岁开始进行结直肠癌筛查，一直持续到75岁。虽然有证据支持CRC筛查总体上带来了实质性的好处，但预计2019年将有145,600例新的CRC病例和51,020例死于CRC。除了筛查和早期发现外，可以进一步降低结直肠癌风险的预防策略将大有裨益，特别是在高危人群中。许多先前的研究表明，使用非甾体抗炎药（NSAIDs）可以降低癌症的风险，包括结直肠癌。然而，它们的长期使用可能伴随着严重的副作用，如胃肠道出血。需要更安全、更有效的方法来长期预防结直肠癌。